GMP cell CDMO I Peace, Inc. obtains accreditation as ISO 17025: 2017 compliant
Starts undertaking quality evaluation and characterization of iPSCs in accordance with ISO standards
PALO ALTO, Calif., Dec. 6, 2023 — Leading GMP cell CDMO I Peace, Inc., specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies, announced that its Palo Alto quality control testing facility has been accredited as ISO 17025: 2017 compliant. The accreditation was certified by ANSI National Accreditation Board, one of the leading accreditation bodies in the world. The tests in the scope of accreditation center on the characterization of iPSCs and include cell count and viability per USP <1046>, detection of pluripotency marker expression by flow cytometry per USP <1027>, and also by immunofluorescence assay. [Read more…]
StemSight Bolsters Leadership Team and Adds Extensive Experience in Cell Therapy Commercialization with Key Hire
In the field of groundbreaking regenerative medicine, StemSight’s aim to cure blindness takes a major leap forward with the strategic appointment of Dr Ross Macdonald as Chief Commercial Officer.
Tampere, Finland, 21.11.23 — StemSight Oy, the leading deep tech company dedicated to eliminating corneal blindness through stem cell technology, proudly announces the appointment of Dr Ross Macdonald to advance the Company’s commercial strategy. With over three decades of pharmaceutical and biopharma industry expertise, Macdonald’s inclusion in StemSight’s team brings a new breadth of experience to the Company. [Read more…]
How 3D Printing with Stem Cells will Alter the Future of Medicine
Without question, 3D printing is one of the most transformative technologies of the 21st century, impacting diverse fields that include medicine, science, technology, manufacturing, military defense, and more. Among its exciting and varied applications, combining 3D printing technologies with stem cells is one of the most exciting.
For this reason, this article explores critical advances in 3D printing and how this technology is creating positive opportunities for stem cell companies and investors.
Using iPS Cells from I Peace, Heartseed Succeeds in Stable Production of High Purity Cardiomyocytes, A Major Step Forward in Advancing Autologous Cardiac Regenerative Medicine
PALO ALTO, Calif., Nov. 1, 2023 — Leading GMP cell CDMO I Peace, Inc., specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies based in Palo Alto, CA, and Heartseed Inc. (“Heartseed”), a Tokyo-based biotechnology company developing iPSC-derived cardiomyocytes for heart failure, have collaborated to generate cardiomyocytes using multiple donor-derived GMP grade iPS cell lines by I Peace, and Heartseed’s proprietary cardiomyocytes differentiation and purification methods. Heartseed has successfully produced high-purity cardiomyocytes consistently from all I Peace manufactured iPS cell lines used in this study. This achievement marks a significant step forward in the realization of autologous cardiac regenerative medicine with I Peace’s personal iPS cell banking service (My Peace), to manufacture and store iPS cells, and induce them into cardiomyocytes for use in autologous cell therapy. [Read more…]
- « Previous Page
- 1
- …
- 28
- 29
- 30
- 31
- 32
- …
- 79
- Next Page »